Effects of Tadalafil on Cognition and Cerebral Hemodynamics in Elderly Patients With Mild Cognitive Impairment
Public ClinicalTrials.gov record NCT07882901. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Assessing the Feasibility of Daily Low Dose Tadalafil and Subsequent Effects on Cognition and Cerebral Vasomotor Reactivity in Elderly Patients With Mild Cognitive Impairment
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The goal of this clinical trial is to determine if taking four weeks of a daily low dose of tadalafil is possible and safe in elderly males and females with mild cognitive impairment. Additionally, we aim to determine if this drug that improves blood flow can improve cognition and functionality of the blood vessels in the brain. The main questions the trial aims to answer are: 1. Will elderly patients with mild cognitive impairment be able to tolerate taking a daily, low dose (5 mg) of tadalafil? 2. Does 5 mg of daily tadalafil improve cerebral vasomotor reactivity (i.e. vascular function) and cognition? Participants will to: 1. Answer questions about your health 2. Take three short thinking and memory tests 3. Have your blood pressure and heart rate checked 4. Have an electrocardiogram 5. Fill out a thinking questionnaire 6. Fill out a suicidality questionnaire 7. Have a brain blood flow test 8. Get three blood tests throughout the study 9. Take tadalafil once daily 10. Monitor your blood pressure twice daily 11. Record any side effects 12. Return after 4 weeks and repeat testing
Study identification
- NCT ID
- NCT07882901
- Recruitment status
- Not yet recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 44 participants
Conditions and interventions
Conditions
Eligibility (public fields only)
- Age range
- 60 Years to 90 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Sep 2026 (Estimated)
- Primary completion
- Feb 20, 2027 (Estimated)
- Completion
- Feb 20, 2027 (Estimated)
- Last update posted
- Oct 20, 2026
2026 – 2027
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Los Angeles Brain Science Project | Santa Monica | California | 90403 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT07882901, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Oct 20, 2026 · Synced Oct 22, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete public registry record, listed eligibility criteria, and available contact information for NCT07882901 live on ClinicalTrials.gov.